ResearcherUniversidad San Pablo CEUActive in the last 2 years
Rafael Álvarez-Gallego
Matched on ORCID iD 0000-0002-3167-8039; OpenAlex author ID A5023415126, A5130972842. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 53
2017: 2 papers · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers
Papers 11
- Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
- A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With N… Co-author DOI 10.1097/coc.0000000000001253↗
- A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
- Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
- Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarc… Co-author DOI 10.1177/17588359241309828↗
- HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
- VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Co-author DOI 10.1136/jitc-2021-003254↗
- Management of hyperbilirubinaemia in pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2018.01.078↗
- From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. Co-author DOI 10.7150/jca.23716↗
- Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. First author DOI 10.1007/s12094-016-1594-x↗
- A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2017.08.003↗
Closest collaborators
The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Teresa Mercade Macarulla · 6 shared papers, 2017–2026 · strength 0.81
- Paper A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancrea… DOI 10.1097/coc.0000000000001253↗
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828↗
- Paper HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaust… DOI 10.1101/2024.08.29.24312704↗
- Antonio Cubillo · 3 shared papers, 2017–2026 · strength 0.52
- Paper A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancrea… DOI 10.1097/coc.0000000000001253↗
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828↗
- Paper A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic a… DOI 10.1016/j.suronc.2017.08.003↗
- Florian Castet · 2 shared papers, 2024–2026 · strength 0.39
- Paper A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancrea… DOI 10.1097/coc.0000000000001253↗
- Paper HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaust… DOI 10.1101/2024.08.29.24312704↗
- Alfredo Carrato Mena · 4 shared papers, 2017–2024 · strength 0.35
- Paper HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaust… DOI 10.1101/2024.08.29.24312704↗
- Paper From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. DOI 10.7150/jca.23716↗
- Paper Management of hyperbilirubinaemia in pancreatic cancer patients. DOI 10.1016/j.ejca.2018.01.078↗
- Berta Laquente · 2 shared papers, 2021–2026 · strength 0.35
- Joaquina Martínez-Galán · 3 shared papers, 2017–2025 · strength 0.34
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828↗
- Paper From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. DOI 10.7150/jca.23716↗
- Paper Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. DOI 10.1007/s12094-016-1594-x↗
- Yolanda Quijano · 2 shared papers, 2017–2026 · strength 0.31
- Paper A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancrea… DOI 10.1097/coc.0000000000001253↗
- Paper A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic a… DOI 10.1016/j.suronc.2017.08.003↗
- Emilio Vicente · 2 shared papers, 2017–2026 · strength 0.31
- Paper A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancrea… DOI 10.1097/coc.0000000000001253↗
- Paper A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic a… DOI 10.1016/j.suronc.2017.08.003↗
- Manuel M. Hidalgo · 4 shared papers, 2017–2021 · strength 0.31
- Paper VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. DOI 10.1136/jitc-2021-003254↗
- Paper From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. DOI 10.7150/jca.23716↗
- Paper Management of hyperbilirubinaemia in pancreatic cancer patients. DOI 10.1016/j.ejca.2018.01.078↗
- Roberto Pazo-Cid · 2 shared papers, 2017–2025 · strength 0.26
- Juli Busquets · 1 shared paper, 2026 · strength 0.25
- Ismael Ghanem · 1 shared paper, 2025 · strength 0.21
- Fernando Garicano Goldaraz · 1 shared paper, 2025 · strength 0.21
- Raúl Rabadán · 1 shared paper, 2024 · strength 0.14
- Alberto Langtry Yáñez · 1 shared paper, 2024 · strength 0.14
- Evangelina López de Maturana · 1 shared paper, 2024 · strength 0.14
- Linda Sharp · 1 shared paper, 2024 · strength 0.14
- Luis Muñoz‐Bellvís · 1 shared paper, 2024 · strength 0.14
- Rita Teresa Lawlor · 1 shared paper, 2024 · strength 0.14
- Gaby J. Strijk · 1 shared paper, 2024 · strength 0.14
- Núria Malats Riera · 1 shared paper, 2024 · strength 0.14
- J. Enrique Domínguez‐Muñoz · 1 shared paper, 2024 · strength 0.14
- William Greenhalf · 1 shared paper, 2024 · strength 0.14
- Christoph W. Michalski · 1 shared paper, 2024 · strength 0.14
- Jorg H. Kleeff · 1 shared paper, 2024 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.